Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics of LY3819469 Following Subcutaneous Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05841277 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05841277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05841277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics of LY3819469 Following Subcutaneous Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2023
Completion date
January 9, 2024
Enrollment
26 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, renal insufficiency